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Abstract 
To determine the specificity of action of indomethacin as an inhibitor of cyclooxygenase in the mammary epithelium, cell proliferation 
and levels of PGE 2 and LTB 4 were quantitated in 13762 MAT rat mammary carcinoma cells treated with 10 -4  to 10 - I °  M 
concentrations of drug. Suppression of proliferation of 13762 MAT cells by indomethacin was associated with reduced levels of both 
PGE 2 and LTB 4. The antiproliferative activity of indomethacin rat mammary carcinoma cells may be modulated through inhibition of 
both cyclooxygenase and lipoxygenase pathways of arachidonic acid metabolism. 
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The role of arachidonic acid (AA) metabolism in breast 
cancer and its relevance as a target for breast cancer 
prevention and therapy have become significant areas of 
research in recent years. AA is metabolized to several 
series of biologically active lipids through a complex 
cascade of enzymatic and non-enzymatic processes; prod- 
ucts of AA metabolism include prostaglandins (PG) and 
thromboxanes (TX) generated by the cyclooxygenase path- 
way, leukotrienes (LT), hydroxyeicosatetraenoic acids 
(HETES), and hydroperoxyeicosatetraenoic acids 
(HPETES) generated through lipoxygenase pathways, and 
epoxye icosat r ieno ic  acids produced by the 
epoxygenase/cytochrome P-450 system. 
AA metabolites (eicosanoids) are pleiotropic modifiers 
of biological responses; biological activities of these com- 
pounds include, but are not limited to, effects on prolifera- 
Abbreviations: AA. arachidonic acid; PG, prostaglandin; TX, throm- 
boxane; LT, leukotriene; HETE, hydroxyeicosatetraenoic ac d; HPETE, 
hydroperoxyeicosatetraenoic acid. 
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tion of normal and neoplastic ells, modulation of inflam- 
matory and other immune responses, and regulation of 
hemostasis (for reviews, see [1-7]). Eicosanoids are pre- 
sent in elevated concentrations in breast cancers in both 
humans and rodents ([8-12]), and are potent regulators of 
the development and growth of breast cancer in experi- 
mental animals ([13-18]). Eicosanoids have been proposed 
as mediators of dietary fat action in rat mammary tumori- 
genesis ([13]). 
Previous work from this laboratory has demonstrated 
that mammary carcinogenesis in rats can be suppressed by 
drugs that inhibit any of several pathways of AA 
metabolism. Drugs with anticarcinogenic a tivity in the rat 
mammary gland include indomethacin and flurbiprofen 
(inhibitors of cyclooxygenase; [14,15]), nordihydrogua- 
iaretic acid (inhibitor of 5-1ipoxygenase; [16]), quinacrine 
(inhibitor of phospholipase A 2 ; [ 17]), and tranylcypromine 
(inhibitor of prostacyclin synthetase; [18]). By contrast, 
imidazole, an inhibitor of thromboxane synthetase, appears 
to enhance mammary cancer induction in animals fed low 
fat diets ([18]). 
Although indomethacin has significant anticarcinogenic 
activity in the rat mammary gland, the compound has been 
demonstrated to promote tumorigenesis in mouse skin 
([19]). One mechanism proposed for the skin tumor pro- 
moting activity of indomethacin is enhancement of the 
biosynthesis of lipoxygenase products associated with cy- 
clooxygenase inhibition ([19]). As such, a critical issue in 
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Fig. 1. A portion of mass spectrum of eicosanoids released from 13762 
MAT rat mammary carcinoma cells. Electrospray mass spectra were 
acquired over the mass range of 50 to 1200 daltons, using a VG 12-250 
quadrupole mass spectrometer quipped with a Vestec Model 611B 
electrospray source. Samples were analyzed by flow injection analysis 
using positive ion electrospray ionization. A summed spectrum of 25 
scans in the VG 'MCA' mode (giving 'continuum' or 'profile' data) was 
generated for each sample. A complete mass spectrum was obtained for 
all the samples. The major peak is unidentified but may represent a
non-eicosanoid entitiy (Courtesy of Dr. Kenneth Tomer, National Institite 
of Environmental Health Sciences, Research Triangle Park, NC). 
identifying the tissue-specific activities of indomethacin s
its influence on specific components of the arachidonic 
acid cascade. Because the products of several pathways of 
arachidonic acid metabolism ay modify cancer induction, 
the specificity of drug action has important implications 
for the utility of indomethacin as a cancer preventive or 
therapeutic agent. The present study was designed to deter- 
mine the effects of indomethacin on the proliferation of rat 
mammary carcinoma cells, and to correlate these effects 
with influences on the generation of cyclooxygenase and 
lipoxygenase products. 
All studies were performed using the 13762 MAT B 
Table 2 
Influence of indomethacin dose on production of PGE~ and LTB4by 
13762 MAT rat mammary adenocarcinoma cells 
Indomethacin Exposure Eicosanoids produced 
dose (M) duration (h) (pg/106 cells) 
PGE 2 LTB 4 
0 (control) I 713 158 
t0 -4 1 0 73 
0 (control) 8 413 150 
10 -4 8 4 28 
0 (control) 1 563 105 
10 - I °  1 675 188 
0 (control) 8 750 148 
10 10 8 825 143 
* lndomethacin solubility necessitated the inclusion of ethanol in the 
diluent for the 10 -4 M concentration ly; ethanol was also included in 
control cultures for experiments involving the 10 4 M concentration of
indomethacin. 
(III) cell line, purchased from the American Type Culture 
Collection (Rockville, MD). The 13762 cell line was de- 
veloped from an ascites tumor derived from a solid mam- 
mary adenocarcinoma induced in a Fischer 344 rat by 
7,12-dimethylbenz[a]anthracene. 13762 MAT cells 
demonstrate both cyclooxygenase and 5-1ipoxygenase ac- 
tivity; the generation of two major products of these 
enzymatic pathways, PGE 2 and LTB 4, by 13762 MAT 
cells was confirmed by mass spectrometry (Fig. 1). 
13762 MAT cells were cultured in modified Dulbecco's 
minimal essential medium (DMEM) containing 5% fetal 
bovine serum, +_indomethacin at graded concentrations 
ranging from 10 4 to l0  -10 M. Parallel cultures were 
incubated in control and indomethacin-treated media con- 
taining 0.02 /zCi tritiated thymidine/ml; at times ranging 
from 1 to 80 h, aliquots of cells were cold-chased with 
unlabelled thymidine (1.0 mg/ml)  for 0.5 h, and were 
solubilized in NaOH and counted. Total cell counts were 
determined using a Coulter counter. Eicosanoids were 
extracted by treating cells for 1.5 h with the calcium 
ionophore A23187, as described by Henke et al. ([20]). 
Levels of PGE 2 and LTB 4 released by mammary tumor 
cells were quantitated using solution phase enzyme im- 
munoassay and radioimmunoassay kits (Advanced Mag- 
Table l 
Influence of indomethacin dose on proliferation of 13762 MAT rat mammary adenocarcinoma cells 
Exposure time (h) Control Indomethacin 10-1° M Indomethacin 10 8 M Indomethacin 10-6 M 
Thymidine Thymidine % of Thymidine % of Thymidine % of 
uptake a uptake control uptake control uptake control 
Indomethacin 10 4 M 
Thymidine % of 
uptake control 
4 1170+91 1600_+28 136.8 1555_+21 132.9 1270_+ 17 108.5 
12 3883 _+ 295 5013 +_ 301 129.1 5420 + 282 139.6 5090 _+ 88 131.1 
20 17057 _ 400 20943 _+ 1053 122.8  20085 _+ 233 117.8 21 835 ___ 940 128.0 
40 50 287 +_ 2183 61 885 +_ 544 123.1 56957 _+ 1509 113.3  57706 + 5461 114.8 
80 58 810 _+ 1386 55 363 4- 8307 94.1 49677 _.% 1471 84.5 64323 + 772 109.4 
125 + 7 10.7 
255 _ 21 6.6 
380 + 26 2.2 
2750 _+ 57 5.5 
587 _+ 49 1.0 
a Expressed as DPM per 106 cells 
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netics, Cambridge, MA). 
As shown in Table 1, the influence of indomethacin on 
proliferation of rat mammary carcinoma cells was dose-re- 
lated. When administered at 10 -4 M, indomethacin sup- 
pressed both cell proliferation (as measured by cell counts) 
and thymidine incorporation, but was not directly cyto- 
toxic. Cell viability (as determined by trypan blue exclu- 
sion) in cultures treated with 10 4 M indomethacin was 
> 95%. The suppression of cell proliferation by 10-4 M 
indomethacin was reversible upon drug removal from the 
culture medium (data not shown). 
By contrast o the antiproliferative activity of ]0 -4 M 
indomethacin, exposure to indomethacin for up to 40 h at 
concentrations of I0 6 M, 10 s M, 10 -~° M resulted in 
modest increases in cell proliferation (Table 1). These 
effects were reversible upon withdrawal of the drug, and 
were not seen in cultures exposed to indomethacin continu- 
ously for 80 h. Although absolute cell counts increased 
throughout the 80-h exposure period, the influence of 
indomethacin dose on the proliferation of 13762 MAT 
cells was essentially constant at all time points between 4 
and 40 h (4, 12, 20, and 40 h). 
The inhibition of cell proliferation induced by the 10 -4 
M concentration of indomethacin was associated with a 
near total (>  99%) suppression of PGE 2 production at 
both 1 and 8 h of exposure (Table 2). This reduction in 
PGE, production in indomethacin-treated cultures is con- 
sistent with many literature reports of its activity as a 
cyclooxygenase inhibitor in other model systems ([21]). 
Interestingly, exposure to indomethacin at 10 4 M also 
suppressed the production of LTB 4 by 13672 MAT cells 
(Table 2). Although this effect appeared to require more 
time to develop and was quantitatively smaller than the 
suppression of PGE 2 biosynthesis, a suppression of ap- 
prox. 80% from control levels was seen at 8 h. 
By contrast to the inhibition of arachidonic acid 
metabolism seen in cells exposed to indomethacin at 10 4 
M, the l0 t 0 M concentration of indomethacin i duced no 
clear suppression of PGE 2 or LTB 4 production, and may 
have been slightly stimulatory to both pathways. This lack 
of inhibition of eicosanoid biosynthesis is consistent with 
the lack of inhibition by 10 -~° M indomethacin on cell 
proliferation in the 13762 model system, and may be 
associated with the modest increases in cell number seen 
in cultures exposed to these doses of drug. 
The results from these studies demonstrate a clear 
dose-response r lationship for the effects of indomethacin 
on proliferation of 13762 MAT cells. Whereas the 10 -4 M 
concentration of indomethacin suppressed mammary can- 
cer cell proliferation, lower (_< l0 6 M) concentrations of
indomethacin stimulated proliferation of these ceils. The 
inhibition of cancer cell proliferation by 10 -4 M indo- 
methacin was associated with a near-total suppression of 
PGE 2 production, thus extending data in other cell systems 
to demonstrate that indomethacin can inhibit arachidonic 
acid cyclooxygenase in rat mammary cancer cells. 
In addition to the expected effect on PGE 2 production, 
high dose indomethacin also suppressed the biosynthesis 
of LTB 4 in rat mammary carcinoma cells. This result 
suggests that the modulation of arachidonic acid catabolism 
by high dose indomethacin is not specific to suppression of 
cyclooxygenase activity; biosynthesis of l ipooxygenase 
products is also suppressed by this drug regimen. The loss 
of antiproliferative activity seen at lower doses of indo- 
methacin was associated with a clear loss of activity in the 
inhibition of arachidonic acid cyclooxygenase and lipoxy- 
genase, and possible stimulation of these enzyme systems. 
Finally, these data provide a direct correlation between 
the efficacy of indomethacin as an inhibitor of mammary 
cancer cell proliferation and activity as inhibitor of arachi- 
donic acid metabolism. The relative importance of the 
activity of indomethacin as a lipoxygenase inhibitor (in 
addition to its well-studied role as a cyclooxygenase in- 
hibitor) is unclear. However, in consideration of the activ- 
ity of a lipooxygenase inhibitor (NDGA) in suppressing 
mammary tumor induction ([16]), the lack of specificity of 
indomethacin action may increase its antitumor activity. 
References 
[1] Samuelsson, B. (1983) Science 220, 568-575. 
[2] McGiff, J.C. (1987) Prevent. Meal. 16, 503-509. 
[3] Karmali, R.A. (1987)Prevent. Med. 16, 493-502. 
[4] Wickremasinghe, R.G. (1988)Prostagland. Leukotri. Essen. Fatty 
Acids 31, 171-179. 
[5] Nicosia, S. and Patrono, C. (1989) FASEB J. 3, 1941-1947. 
[6] Naor, Z. (1991) Mol. Ceil. Endocrinol, 80, C181-C186. 
[7] Holtzman, M.J. (1992)Annu. Rev. Physiol. 54, 303-329. 
[8] Bennett. A., McDonald, A.M., Stamford. I.F., Charlier, E.M., Simp- 
son, J.S. and Zebro, T. (1977) Lancet ii, 624-626. 
[9] Karmali. R.A., Welt, S., Thaler, H.T.. and Lefevre, F. (1983) Brit. J. 
Cancer, 48. 689-696. 
[101 Vergote, I.B., Laekman, G.M., Keersmaekers, G.H., Vyttenbroeck, 
F.L., Verderheyden, J.S., Albertyn, G.P., Haensch, C.F., DeRoy, 
G.J., and Herman, A.G. (1985) Brit. J. Cancer, 51, 827-836. 
[11] Karmali, R.A., Thaler, H.T.. and Cohen, L.A. (1983) Eur. J. Cancer 
Clin. Oncol. 19. 817-823. 
[12] Tan, W.C., Privett, O.S., and Goldyne, M.E. (1974) Cancer Res.. 24, 
3229-3231. 
[13] Carter, C.A.. Milholland, R.J., Shea. W. and Ip, M.M. (1983) 
Cancer Res. 43, 3559-3562. 
[14] McCormick, D.L. and Moon, R.C. (1983) Br. J. Cancer 48, 859-861. 
[15] McCormick, D.L.. Madigan, M.J. and Moon, R.C. (1985) Cancer 
Res. 45, 1803-1808. 
[ 16] McCormick, D.L. and Spicer, A.M. (1987) Cancer Lett. 37, 139-146. 
[17] McCormick, D.L. Carcinogenesis (1988) 9, 175-178. 
[18] McCormick, D.L., Spicer, A.M. and Hollister, J.L. (1989) Cancer 
Res. 49, 3168-3172. 
[19] Fischer, S.M., Gleason, G.L., Mills, G.D. and Slaga, T.J. (1980) 
Cancer Lett. 10. 343-350. 
[20] Henke, D.C.. Kouzan, S. and Eling, T.E. (1984) Anal. Biochem. 
140, 87-94, 
[21] Marnett, L.J. (1992)Cancer Res., 52, 5575-5589. 
